Novo Nordisk, a healthcare company renowned for its advancements in diabetes care, has announced a groundbreaking agreement to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion. 

This move marks Novo Nordisk's entry into the domain of cardiovascular disease therapeutics and underscores its commitment to addressing unmet needs in this critical area of healthcare.

Cardior Pharmaceuticals, a clinical-stage biopharmaceutical company, specializes in the discovery and development of RNA-based therapies aimed at preventing, repairing, and reversing heart diseases. Central to Cardior's approach is the targeting of distinctive non-coding RNAs, offering a promising platform for addressing the root causes of cardiac dysfunctions and achieving lasting patient impact.

At the heart of the acquisition is Cardior's lead compound, CDR132L, currently in phase 2 clinical development for the treatment of heart failure. Designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132, CDR132L demonstrates transformative potential as a disease-modifying therapy for heart failure.

Martin Holst Lange, Executive Vice President for Development at Novo Nordisk, expressed enthusiasm about the acquisition, stating, "By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programs across all phases of clinical development."

The acquisition aligns with Novo Nordisk's broader strategy to establish a presence in cardiovascular disease therapy. Through internal and external innovation, the company aims to build a focused and impactful portfolio of therapies to address the significant unmet needs in cardiovascular disease, which remains the most common cause of death globally.

The transaction, subject to regulatory approvals and customary conditions, is expected to close in the second quarter of 2024. Novo Nordisk intends to fund the acquisition from its financial reserves, with no anticipated impact on its previously communicated operating profit outlook for 2024 or the ongoing share buy-back program.

Claudia Ulbrich, MD, CEO, and co-founder of Cardior, expressed confidence in the partnership with Novo Nordisk, stating, "Novo Nordisk is the ideal partner based on its deep clinical and commercial expertise combined with its resources to accelerate our late-stage development program."

Heart failure, a chronic and progressive condition affecting more than 65 million people globally, poses significant challenges in healthcare. While current therapies can slow disease progression, the condition remains incurable, highlighting the urgent need for innovative treatments like CDR132L.